SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (207)10/1/2018 7:27:22 PM
From: A.J. Mullen  Respond to of 294
 
That looks interesting to me. This paper gives some details, ncbi.nlm.nih.gov
Ashley



To: Miljenko Zuanic who wrote (207)10/1/2018 9:10:38 PM
From: tuck  Read Replies (2) | Respond to of 294
 
Competitors coming out of the woodwork. Have we mentioned ALX Oncology's version here yet?

ALX148

Haven't had a position in a while. Apparently, TRIL can dose a bit higher than they thought, but they sure lost some time getting to that point, and now their leadership and safety advantage seems to have evaporated.

Might sell puts if it nears $5, though, as it's till in the race and undervalued relative to others in the space.

Cheers, Tuck



To: Miljenko Zuanic who wrote (207)10/3/2018 3:23:48 PM
From: A.J. Mullen  Read Replies (1) | Respond to of 294
 
I'm out! Finally had my order filled after chasing down the price for a couple of days. Thanks Miljenko for the heads up regarding competition, and to Ric for his warnings wrt management over years.

Thanks also Miljenko for your warning sometime back regarding Exelexis. I had already unloaded most of my holding of that, but you encouraged me to get out completely, which saved me money.

Ashley


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News